Form 4: Cytokinetics CFO Lee Sung Reports Routine Stock Transaction Following RSU Vesting

Cytokinetics' Executive Vice President and Chief Financial Officer, Lee Sung, reported a routine disposition of 4,965 shares of common stock for tax withholding purposes following the vesting of restricted stock units.

Summary

• Lee Sung, EVP and Chief Financial Officer of Cytokinetics Inc. (CYTK), reported a transaction on June 2, 2025.
• The transaction involved the disposition of 4,965 shares of common stock at a price of $31.21 per share.
• This disposition was for tax withholding purposes, incident to the vesting of 13,874 restricted stock units (RSUs).
• After the withholding, Mr. Lee received 8,909 net shares of common stock.
• Following this transaction, Mr. Lee beneficially owns 69,477 shares of Cytokinetics common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects the vesting of executive compensation (RSUs), which is a positive event for the executive and a routine part of compensation plans. The disposition is for tax purposes, not a voluntary sale, making the overall impact neutral to slightly positive.

Positives

• The vesting of 13,874 restricted stock units indicates a successful milestone for executive compensation and retention.
• Mr. Lee received 8,909 net shares, increasing his direct beneficial ownership in the company.

Negatives

• The disposition of 4,965 shares was for tax withholding, not a voluntary sale, and is a standard part of RSU vesting.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: This is a routine compensation event for an executive and does not typically have a significant direct impact on the share price or company strategy.
• Employees: Reflects standard executive compensation practices.

Key Dates

Keywords

Cytokinetics, CYTK, Lee Sung, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership